#USA #Philadelphia #Health Technology #Field Medical #VT Ablation

Field Medical's Groundbreaking Presentation at VT Symposium 2025

Field Medical, Inc., a frontrunner in the realm of medical technology, particularly in the area of pulsed field ablation (PFA) for treating ventricular tachycardia (VT), has made headlines with its announcement of significant new data to be presented at the upcoming 20th Annual International Symposium on Ventricular Arrhythmias, scheduled for October 10-11, 2025, in Philadelphia.

In a compelling showcase, Field Medical is set to participate in three pivotal sessions during the symposium, including a presentation of promising outcomes from its FieldForce™ Ablation System. This system represents a pioneering effort in the application of focused contact-force PFA technology specifically designed for VT patients. The unveiling of six-month follow-up data from first-in-human trials marks a crucial milestone in the journey toward innovative solutions for VT treatment, a condition that has long demanded novel approaches due to its complexity and potential lethality.

Mark Wisniewski, the chairman of the board at Field Medical, remarked on the significance of these findings: "Our data serves to reinforce the urgent need for innovation in VT care. What we present at the VT Symposium underscores not only the effectiveness of our PFA technology but also the necessity for continued advancement in the treatment of these challenging arrhythmias."

Scientific Presentations Highlighting Innovative Research

Among the highlights slated for presentation in the Late-Breaking Clinical Trial Competition, Dr. Vivek Reddy will share findings from the trial titled High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: Final 6-Month Outcomes of the First-in-Human VCAS Trial. Scheduled for October 10, this session aims to provide an in-depth look at the clinical efficacy of the FieldForce™ Ablation System.

Additionally, on October 11, Dr. Cory Tschabrunn will present insights derived from a porcine model of chronic infarction, focusing on high voltage PFA applications for VT, thereby elucidating preclinical perspectives that could inform future human treatments.

A pre-recorded live case demonstration by Dr. Reddy will further illustrate the practical applications of image-guided high voltage VT ablation, providing attendees with direct insights into the operation and effectiveness of the new technology.

Company Leadership Strengthening Innovation Focus

In tandem with these key presentations, Field Medical is also reorienting its internal structure to bolster innovation and strategic growth initiatives. Steven Mickelsen, MD, who co-founded the company, has stepped into the role of Chief Technology Officer (CTO), now overseeing both clinical innovation and the evolution of the FieldForce™ Ablation System. Meanwhile, Kit Schneider has been appointed as Chief Strategy Officer (CSO), with a mandate to enhance corporate strategy and sustain growth through effective partnerships.

Schneider commented on the company's direction, stating, "Field Medical has made remarkable progress in introducing pulsed field ablation techniques into the ventricle. My focus will be on positioning the company for an elevated stage of growth, solidifying partnerships, and ensuring our readiness to deliver these innovations to medical professionals and patients around the globe."

About Field Medical, Inc.

Founded in 2022, Field Medical, Inc. is a clinical-stage medtech firm dedicated to revolutionizing PFA solutions for complex cardiac arrhythmias. The FieldForce™ Ablation System merges advanced catheter design with patented FieldBending™ energy technology. This cutting-edge approach aims to provide safe, precise, and effective ablation therapy, thereby enhancing outcomes for patients dealing with both ventricular and atrial arrhythmias. In 2024, Field Medical received Breakthrough Device Designation and entered the FDA TAP Pilot Program for its VT indication—a testament to the promising future of its innovative technology.

For further insights and up-to-date information, visit Field Medical's official website and follow the company across social media platforms like LinkedIn, X, and YouTube. Please remember, the FieldForce™ Ablation System is currently an investigational device limited to research applications under federal law.

For media inquiries, please contact:
Holly Windler
Phone: (619) 929-1275
Email: [email protected]